154 related articles for article (PubMed ID: 16699847)
1. MR imaging of CNS tumors: are all contrast agents created the same?
Essig M
Neuroradiology; 2006 Apr; 48 Suppl 1():3-8. PubMed ID: 16699847
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
Zhang HM; Ouyang H; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-perfusion in intra-axial brain tumors with high relaxivity contrast agents.
Cotton F
Neuroradiology; 2006 Apr; 48 Suppl 1():34-40. PubMed ID: 16699850
[TBL] [Abstract][Full Text] [Related]
4. Gadobenate dimeglumine (MultiHance) in MR imaging of the CNS: studies to assess the benefits of a high relaxivity contrast agent.
Essig M
Acad Radiol; 2005 May; 12 Suppl 1():S23-7. PubMed ID: 16106542
[TBL] [Abstract][Full Text] [Related]
5. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
6. Pulse repetition time and contrast enhancement: simulation study of Gd-BOPTA and conventional contrast agent at different field strengths.
Yrjänä SK; Vaara T; Karttunen A; Koivukangas J
Invest Radiol; 2008 Apr; 43(4):267-75. PubMed ID: 18340251
[TBL] [Abstract][Full Text] [Related]
7. Gadobenate dimeglumine as a contrast agent for dynamic breast magnetic resonance imaging: effect of higher initial enhancement thresholds on diagnostic performance.
Sardanelli F; Fausto A; Esseridou A; Di Leo G; Kirchin MA
Invest Radiol; 2008 Apr; 43(4):236-42. PubMed ID: 18340247
[TBL] [Abstract][Full Text] [Related]
8. Protocol design for high relaxivity contrast agents in MR imaging of the CNS.
Essig M
Eur Radiol; 2006 Nov; 16 Suppl 7():M3-7. PubMed ID: 18655261
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with MultiHance in CNS imaging.
Essig M
Eur Radiol; 2003 Nov; 13 Suppl 3():N3-10. PubMed ID: 15015875
[TBL] [Abstract][Full Text] [Related]
10. [Enhanced MR-angiography (CE-MRA) of the supraaortic arteries: dose reduction with a contrast agent of high relaxivity (Gd-BOPTA)].
Friese S; Klose U; Kastrup A; Krapf H; Küker W
Rofo; 2003 Oct; 175(10):1363-7. PubMed ID: 14556105
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance coronary angiography: comparison between a Gd-BOPTA- and a Gd-DTPA-enhanced spoiled gradient-echo sequence and a non-contrast-enhanced steady-state free-precession sequence.
Nassenstein K; Breuckmann F; Hunold P; Barkhausen J; Schlosser T
Acta Radiol; 2009 May; 50(4):406-11. PubMed ID: 19308763
[TBL] [Abstract][Full Text] [Related]
12. Initial experience on utility of gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted MR cholangiography in diagnosis of acute cholecystitis.
Akpinar E; Turkbey B; Karcaaltincaba M; Balli O; Akkapulu N; Balas S; Tirnaksiz B; Akata D; Akhan O
J Magn Reson Imaging; 2009 Sep; 30(3):578-85. PubMed ID: 19711404
[TBL] [Abstract][Full Text] [Related]
13. Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography of the supraaortic vessels at 3 Tesla.
Bueltmann E; Erb G; Kirchin MA; Klose U; Naegele T
Invest Radiol; 2008 Oct; 43(10):695-702. PubMed ID: 18791411
[TBL] [Abstract][Full Text] [Related]
14. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
[TBL] [Abstract][Full Text] [Related]
15. Contrast-enhanced MR imaging of the spine: when, why and how? How to optimize contrast protocols in MR imaging of the spine.
Colosimo C; Cianfoni A; Di Lella GM; Gaudino S
Neuroradiology; 2006 Apr; 48 Suppl 1():18-33. PubMed ID: 16699849
[TBL] [Abstract][Full Text] [Related]
16. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents.
Giesel FL; von Tengg-Kobligk H; Wilkinson ID; Siegler P; von der Lieth CW; Frank M; Lodemann KP; Essig M
Invest Radiol; 2006 Mar; 41(3):222-8. PubMed ID: 16481904
[TBL] [Abstract][Full Text] [Related]
17. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
18. Gadobenate dimeglumine-enhanced MR imaging of patients with CNS diseases.
Maravilla KR
Eur Radiol; 2006 Nov; 16 Suppl 7():M8-15. PubMed ID: 18655262
[TBL] [Abstract][Full Text] [Related]
19. Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications.
Essig M; Weber MA; von Tengg-Kobligk H; Knopp MV; Yuh WT; Giesel FL
Top Magn Reson Imaging; 2006 Apr; 17(2):89-106. PubMed ID: 17198225
[TBL] [Abstract][Full Text] [Related]
20. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla.
Pintaske J; Martirosian P; Graf H; Erb G; Lodemann KP; Claussen CD; Schick F
Invest Radiol; 2006 Mar; 41(3):213-21. PubMed ID: 16481903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
